Krystal Biotech Inc (KRYS)

Fixed asset turnover

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Revenue (ttm)	US$ in thousands	102,227	56,573	9,365	809	809	0	0	0	0	0	0	0	0	0	0	0	542	1,125	1,342	1,515
Property, plant and equipment	US$ in thousands	160,011	161,202	164,029	163,737	163,073	161,684	157,786	151,214	136,927	112,355	78,642	44,972	33,883	30,876	17,512	13,215	10,264	8,475	6,863	5,961
Fixed asset turnover		0.64	0.35	0.06	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.13	0.20	0.25

March 31, 2024 calculation

Fixed asset turnover = Revenue (ttm) ÷ Property, plant and equipment
= $102,227K ÷ $160,011K
= 0.64

The fixed asset turnover ratio for Krystal Biotech Inc has shown significant fluctuations over the past few quarters. In the most recent quarter, as of March 31, 2024, the fixed asset turnover ratio increased to 0.64 from 0.35 in the previous quarter. This indicates that the company generated $0.64 in revenue for every dollar invested in fixed assets during the period.

However, looking back over the past few quarters, the fixed asset turnover ratio had been relatively low, with a significant decline in the ratio in the September 2023 quarter to 0.06. This could suggest inefficiency in utilizing fixed assets to generate revenue during that period.

It is also worth noting that in several quarters, including the last three quarters of 2021 and all quarters in 2020, the fixed asset turnover ratio was reported as 0.00, indicating very low or negligible revenue generation from fixed assets during those periods.

Overall, the recent increase in the fixed asset turnover ratio for Krystal Biotech Inc is a positive sign, but the company should continue to monitor and improve the efficiency of its fixed asset utilization to ensure sustainable revenue generation.